Morgan Stanley Direct Lending Fund (MSDL) is currently trading at a 32% discount to its net asset value due to sector-wide pressures and a worsening credit portfolio. Non-accrual loans have increased to 2.9% of cost, leading to declines in net investment income per share and NAV, with dividend coverage now at just 1.00×. Despite strong liquidity and moderate leverage, credit stability remains uncertain. The fund's dividend, yielding 13.6%, appears secure for the moment, but any further credit deterioration or reduced coverage could prompt a reassessment of its rating and outlook.
Morgan Stanley Direct Lending Fund is discussed here, with Pluang market data providing context. Of 142 Financials-sector US stocks priced on Pluang, 17 rose and 125 fell as of Oct 14, 2026 22:51 WIB. Notable movers include State Street Corporation at USD 162.75 with a 6.46% decline, Bank of America Corp at USD 50.70 with a 6.04% drop and a 76% sell order activity, and Progressive Corp at USD 209.44 with a 6.03% decrease and 100% buy order activity.
Jefferies has maintained a Buy rating on Big Yellow Group despite recent stock declines, citing the company's strong fundamentals including freehold properties and solid cash flows. Activist investor Ancora, holding over 4% of shares, is pushing Big ...
Fastenal reported strong Q3 2026 earnings, beating analyst expectations with EPS of $0.35 and revenue of $2.46 billion. The company saw a 20% rise in net income to $401.6 million and a 15.5% increase in revenue driven by robust manufacturing demand, ...
Remittix announced the public launch of its RTX token on November 24, 2026, marking the end of its presale phase which raised over $32 million from 40,000 participants. The project is testing its PayFi platform, which enables crypto-to-fiat and fiat-...
The global microbiology testing market is projected to grow rapidly at a compound annual growth rate (CAGR) of approximately 9% from 2026 to 2034, reaching a market size of $13.7 billion by 2034. This growth is driven by the rising prevalence of infe...
H.C. Wainwright raised its price target for Alector from $5.00 to $8.00, maintaining a Buy rating due to progress in its neurodegenerative disease pipeline. Alector develops treatments for Alzheimer's and Parkinson's using its Brain Carrier platform ...
